Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder worldwide, is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here's his tips for how to use them successfully.

But don’t race to ask your doctor for a dual prescription just yet, she says. While Faubion’s initial research suggests that combining MHT and a GLP-1 may help with weight loss, more studies ...

Of the GLP-1 group, 97.5% of patients were on Novo Nordisk’s popular diabetes and obesity GLP-1 semaglutide—sold as Wegovy, Ozempic and in oral form as Rybelsus—while 2.5% took Sanofi’s ...

3. On GLP-1 drugs, get comfortable with being uncomfortable. The great thing about these drugs, says Kessler, is that they allow you to relearn how to eat. But that comes with some caveats. GLP-1 ...

NPR Advice for trying GLP-1 drugs for weight loss from a doctor who's been there. Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity.